查詢結果分析
相關文獻
- Ntrathecal Acnu Against Experimental Leptomeningeal Tumors
- Nasopharyngeal Carcinoma with Leptomeningeal Dissemination: Case Report
- Immunohistochemical Demonstration with Anti-Bromodeoxyuridine Monoclonal Antibody in Experimental Meningeal Carcinomatosis Model
- Isolated Acute Hearing Loss as the Presenting Symptom of Leptomeningeal Carcinomatosis
頁籤選單縮合
題名 | Ntrathecal Acnu Against Experimental Leptomeningeal Tumors=膜癌病之ACNU髓腔內治療 |
---|---|
作者姓名(中文) | 黃祖源; 洪純隆; | 書刊名 | The Kaohsiung Journal of Medical Sciences |
卷期 | 13:10 1997.10[民86.10] |
頁次 | 頁626-630 |
分類號 | 416.291 |
關鍵詞 | 膜癌病; 髓腔內治療; ACNU; Bromodeoxyuridine; Intrathecal chemotherapy; |
語文 | 英文(English) |
中文摘要 | 惡性神經膠瘤或癌症的腦膜轉移所造成之惡性軟腦膜腫瘤是一種致命的病態,其發生率約為惡性神經膠瘤之10-20%,最近且有增加的傾向,目前尚無有效之治療法,其平均生存期間自診斷日起平均約18週。本研究以生理病態和其類似的腦膜癌病大白鼠為對象,做ACNU髓腔內治療效果和細胞動力學方面之探討。 以Walker 256 carcinosarcoma細胞注入大白鼠之大池內作成腦膜癌病模型,注入後第五日再以ACNU 1.5mg/kg髓腔內治療,結果其平均生存日期較無治療群有意義地延長。 溴脫氧尿核甘 (BrdU) 為胸甘 (thymidine) 之類似物,於細胞合成期被細胞核撮入後,可被抗溴脫氧核甘單一同本生物抗體以免疫組織化學ABC染色法標識,被標識細胞的比例 (標識率:Ll) 於治療前後的變化作為療效的判定。腫瘤細胞注入後第五日,其Ll約為34%,以ACNU髓腔內治療後12至48小時,Ll降低至百分之十幾,96小時後Ll回升到治療前之程度。 腦膜癌病之早期,以ACNU髓腔內治療是一種可以期待的有效療法。 |
英文摘要 | Therapeutic efficacy and cell kinetics of intrathecal ACNU, 3-(4-amino- 2-methyl-5-pyrimidinyl) methyl-i- (2-chloroethyl)- 1-nitrosourea, were investigated in experimental meningeal carcinomatosis rats. Therapeutic effect of intrathecal ACNU (IT ACNU) against meningeal carcinomatosis model was evaluated in rats induced by intracisternal Inoculation of Walker 256 carcinosarcoma cells. The median survival time of the rats treated with IT ACNU 1.5 mg/kg on day 5 after tumor inoculation was significantly increased by 145% as compared with that of non- treatment rats. The cell kinetics was studied immunohistochemically using indirect immunoperoxidase method with bromodeoxyuridine (BrdU) and anti-BrdU monoclonal antibody (Becton-Dickinson). The meningeal carcinomatosis rats were treated with IT ACNU (1.5 mg/kg) on the fifth day after tumor inoculation. Before and 12, 24, 48, 96 or 144 hours after treatment, the rats received intravenous BrdU (200 mg/kg) Injection. Thirty minutes later, the rats were sacrificed and the brains were removed. Brain sections were stained immunohistochemically with anti-BrdU monoclonal antibody. Labeling index (LI) which represented the percentage of tumor cells in synthetic phase was obtained by counting immunoreactive cells under the microscope. Before treatment, LI was around 34% on day 5 after tumor inoculation and dropped to below 20% 12 to 48 hours after IT ACNU. However, it increased to around 36% on day 4 after IT ACNU. The antineoplastic effect of IT ACNU against meningeal carcinomatosis rats might he expected in the early stage of intrathecal administration. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。